Vanta Bioscience Ltd. shows extreme financial distress with negative growth metrics and high debt levels, positioning it as a high-risk investment. However, its low price-to-book and price-to-sales ratios suggest a potential for value recovery if operational issues are addressed. Syngene International Ltd. stands out as a strong performer with solid profitability and growth metrics.

• • Vanta Bioscience has the lowest revenue growth and EPS, along with the highest debt-to-equity ratio among peers.
• • Syngene International leads in profitability with strong ROE and revenue growth.
• • Just Dial is a value pick with the lowest PE ratio, indicating potential undervaluation.